Incidence of hematological toxicities on bispecifics for acute lymphoblastic leukemia published trials
| Reference . | Population . | Drug/target . | N* . | Anemia** . | Neutropenia** . | Thrombocytopenia** . | Febrile neutropenia** . | Lymphopenia** . | Low IgG** . | HLH** . | DIC** . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kantarjian et al. (2017)9 | Adult R/R ALL | Blinatumomab CD19 × CD3 | 267 | 69 (25.8%)/NA | NA/101(37.8%) | 47(17.6%)/NA | NA/57(21.3%) | NA/4(1.5%) | 16(6%)/ 7(2.6%) | 4(1.5%)/ 4(1.5%) | NA/NA |
| Topp et al. (2015)8 | Adult R/R ALL | Blinatumomab CD19 × CD3 | 188 | 38(20%)/ 27(14%) | 33(17%)/ 30(16%) | 21(11%)/16(8%) | 53(28%)/ 48(25%) | NA/NA | NA/NA | NA/NA | 4(2%)/NA |
| Locatelli et al. (2022)10 | Pediatric R/R ALL | Blinatumomab CD19 × CD3 | 110 | 20(18.2%)/ 5(4.5%) | 11(10%)/ 10(9.1%) | 22(20%)/16(14.5%) | NA/ 10(9.1%) | NA/NA | NA/NA | NA/NA | 1(0.9%)/ 1(0.9%) |
| Reference . | Population . | Drug/target . | N* . | Anemia** . | Neutropenia** . | Thrombocytopenia** . | Febrile neutropenia** . | Lymphopenia** . | Low IgG** . | HLH** . | DIC** . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kantarjian et al. (2017)9 | Adult R/R ALL | Blinatumomab CD19 × CD3 | 267 | 69 (25.8%)/NA | NA/101(37.8%) | 47(17.6%)/NA | NA/57(21.3%) | NA/4(1.5%) | 16(6%)/ 7(2.6%) | 4(1.5%)/ 4(1.5%) | NA/NA |
| Topp et al. (2015)8 | Adult R/R ALL | Blinatumomab CD19 × CD3 | 188 | 38(20%)/ 27(14%) | 33(17%)/ 30(16%) | 21(11%)/16(8%) | 53(28%)/ 48(25%) | NA/NA | NA/NA | NA/NA | 4(2%)/NA |
| Locatelli et al. (2022)10 | Pediatric R/R ALL | Blinatumomab CD19 × CD3 | 110 | 20(18.2%)/ 5(4.5%) | 11(10%)/ 10(9.1%) | 22(20%)/16(14.5%) | NA/ 10(9.1%) | NA/NA | NA/NA | NA/NA | 1(0.9%)/ 1(0.9%) |
ALL, acute lymphoblastic leukemia; DIC, disseminated intravascular coagulation; HLH, hemophagocytic lymphohystiocytosis; NA, not available; R/R, relapsed/refractory.
N is the population considered for that extracted data, which may be the whole cohort or a subpopulation.
Adverse event, any grade(%)/grade ≥3(%).